<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>CatsWannaBeCats.Com | Kendall Matthiesen | Activity</title>
	<link>https://www.catswannabecats.com/members/auntperiod7/activity/</link>
	<atom:link href="https://www.catswannabecats.com/members/auntperiod7/activity/feed/" rel="self" type="application/rss+xml" />
	<description>Activity feed for Kendall Matthiesen.</description>
	<lastBuildDate>Wed, 24 Jun 2026 08:20:47 -0400</lastBuildDate>
	<generator>https://buddypress.org/?v=7.2.0</generator>
	<language>en-CA</language>
	<ttl>30</ttl>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>2</sy:updateFrequency>
	
						<item>
				<guid isPermaLink="false">5bc60c713ce00e3827e9216c269a2da0</guid>
				<title>Kendall Matthiesen posted an update: This evidence- and consensus-based guideline on the [&#133;]</title>
				<link>https://www.catswannabecats.com/activity/p/25527/</link>
				<pubDate>Mon, 09 Jun 2025 07:39:36 -0400</pubDate>

									<content:encoded><![CDATA[<p>This evidence- and consensus-based guideline on the treatment of psoriasis vulgaris was developed following the EuroGuiDerm Guideline and Consensus Statement Development Manual. The second part of the guideline provides guidance for specific clinical and comorbid situations such as treating psoriasis vulgaris patient with concomitant psoriatic&hellip;<span class="activity-read-more" id="activity-read-more-25527"><a href="https://www.catswannabecats.com/activity/p/25527/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">03225d515f6eaa14641fc106c0aee0b5</guid>
				<title>Kendall Matthiesen posted an update: ry conditions consistent with biocontainment level 2. This [&#133;]</title>
				<link>https://www.catswannabecats.com/activity/p/23245/</link>
				<pubDate>Sun, 08 Jun 2025 07:46:52 -0400</pubDate>

									<content:encoded><![CDATA[<p>ry conditions consistent with biocontainment level 2. This assay offers promise also in evaluating immunogenicity of spike glycoprotein-based candidate vaccines in the near future.</p>
<p> Quebec is one of the Canadian provinces with the highest rates of cancer incidence and prevalence. A study by the Rossy Cancer Network (RCN) of McGill university&hellip;<span class="activity-read-more" id="activity-read-more-23245"><a href="https://www.catswannabecats.com/activity/p/23245/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">96219018736c021fb05fe27c632fc3ae</guid>
				<title>Kendall Matthiesen posted an update: 3-47.4%). Declines in vitamin C intake is driven largely by [&#133;]</title>
				<link>https://www.catswannabecats.com/activity/p/8504/</link>
				<pubDate>Sat, 31 May 2025 21:16:34 -0400</pubDate>

									<content:encoded><![CDATA[<p>3-47.4%). Declines in vitamin C intake is driven largely by decreases in fruit juice coupled with modest increases in whole fruit. Due to associations between vitamin C intake and numerous health outcomes these trends warrant careful monitoring moving forward.Polymer templates play an essential role in the robust infiltration-based synthesis of&hellip;<span class="activity-read-more" id="activity-read-more-8504"><a href="https://www.catswannabecats.com/activity/p/8504/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">1567a430eb0fb9240bdbf4d37caa153e</guid>
				<title>Kendall Matthiesen became a registered member</title>
				<link>https://www.catswannabecats.com/activity/p/8247/</link>
				<pubDate>Sat, 31 May 2025 20:54:13 -0400</pubDate>

				
									<slash:comments>0</slash:comments>
				
							</item>
		
	</channel>
</rss>